MX2009001412A - Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. - Google Patents

Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.

Info

Publication number
MX2009001412A
MX2009001412A MX2009001412A MX2009001412A MX2009001412A MX 2009001412 A MX2009001412 A MX 2009001412A MX 2009001412 A MX2009001412 A MX 2009001412A MX 2009001412 A MX2009001412 A MX 2009001412A MX 2009001412 A MX2009001412 A MX 2009001412A
Authority
MX
Mexico
Prior art keywords
vaccines
methods
making
administering
protein matrix
Prior art date
Application number
MX2009001412A
Other languages
English (en)
Spanish (es)
Inventor
John J Mekalanos
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX2009001412A publication Critical patent/MX2009001412A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
MX2009001412A 2006-08-07 2007-08-07 Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. MX2009001412A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83594406P 2006-08-07 2006-08-07
US93376407P 2007-06-08 2007-06-08
PCT/US2007/017528 WO2008021076A2 (fr) 2006-08-07 2007-08-07 Vaccins à base de matrice protéique et procédés de fabrication et d'administration de tels vaccins

Publications (1)

Publication Number Publication Date
MX2009001412A true MX2009001412A (es) 2009-04-24

Family

ID=39082551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001412A MX2009001412A (es) 2006-08-07 2007-08-07 Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.

Country Status (12)

Country Link
US (3) US8642042B2 (fr)
EP (2) EP2056871B1 (fr)
JP (2) JP5745221B2 (fr)
KR (1) KR101446238B1 (fr)
AU (1) AU2007284878B2 (fr)
BR (1) BRPI0715396B8 (fr)
CA (1) CA2660022C (fr)
DK (1) DK2056871T3 (fr)
ES (1) ES2658851T3 (fr)
MX (1) MX2009001412A (fr)
TW (1) TWI565713B (fr)
WO (1) WO2008021076A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007284878B2 (en) 2006-08-07 2013-01-17 President And Fellows Of Harvard College Protein matrix vaccines and methods of making and administering such vaccines
US8524394B2 (en) * 2007-11-22 2013-09-03 Samsung Sdi Co., Ltd. Negative electrode and negative active material for rechargeable lithium battery, and rechargeable lithium battery including same
WO2010027473A2 (fr) 2008-09-03 2010-03-11 Board Of Trustees Of Michigan State University Entérotoxine thermostable d'escherichia coli immunogène
WO2011017101A2 (fr) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Procédé de production de vaccins à protéine-carbohydrate à niveau réduit de carbohydrate libre
KR20120104178A (ko) * 2009-09-09 2012-09-20 메트리박스 리써치 앤 디벨롭먼트 코포레이션 면역원성이 개선된 단백질 매트릭스 백신
US20110135689A1 (en) * 2009-11-30 2011-06-09 University Of Iowa Research Foundation Vaccine, therapeutic composition and methods for treating or inhibiting francisella tularenis
SG181750A1 (en) 2009-12-17 2012-07-30 Fina Biosolutions Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
NZ602971A (en) 2010-04-23 2014-11-28 Serum Inst India Ltd Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
WO2012023008A2 (fr) * 2010-05-03 2012-02-23 Dcb-Usa Llc Conjugaison de polysaccharide à une entérotoxine thermolabile (lt) d'e.coli détoxifiée, utilisée comme vaccin
US9724401B2 (en) 2011-05-18 2017-08-08 Matrivax, Inc. Protein matrix vaccine compositions including polycations
NZ721184A (en) 2011-09-30 2018-08-31 Dana Farber Cancer Inst Inc Therapeutic peptides
WO2014111724A1 (fr) 2013-01-18 2014-07-24 London School Of Hygiene And Tropical Medicine Méthode de glycosylation
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
EP2970908B1 (fr) 2013-03-15 2019-12-25 Dana-Farber Cancer Institute, Inc. Peptides thérapeutiques
WO2015073831A1 (fr) * 2013-11-15 2015-05-21 Liquidia Technologies, Inc. Particules de type conjugué virtuel
KR102049826B1 (ko) * 2014-01-21 2019-12-03 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
EP3145953A1 (fr) * 2014-05-21 2017-03-29 Dana-Farber Cancer Institute, Inc. Procédés de traitement du cancer avec des anticorps anti bip ou anti mica
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2018009906A1 (fr) * 2016-07-08 2018-01-11 President And Fellows Of Harvard College Conjugués cellules entières – protéines, et procédés de fabrication de ces derniers
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018227177A1 (fr) * 2017-06-10 2018-12-13 Inventprise, Llc Vaccins conjugués multivalents avec des polysaccharides conjugués bivalents ou multivalents qui confèrent une immunogénicité et une avidité améliorées
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3079111A1 (fr) 2017-10-13 2019-04-18 The Research Foundation For The State University Of New York Conception de vaccin complet contre la progression de maladies commensales
CN111683678B (zh) 2017-12-06 2024-01-26 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
WO2020121159A1 (fr) * 2018-12-12 2020-06-18 Pfizer Inc. Conjugués polysaccharide-protéine immunogènes à hétéroantigènes multiples et leurs utilisations
TWI788610B (zh) 2018-12-19 2023-01-01 美商默沙東有限責任公司 包含肺炎鏈球菌多醣-蛋白質結合物之組合物及其使用方法
CN114129719A (zh) * 2021-12-03 2022-03-04 张公义 广谱疫苗的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4761470A (en) * 1985-12-16 1988-08-02 Merck & Co., Inc. Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
WO1992017436A1 (fr) 1991-03-28 1992-10-15 Holmes, Michael, John Agent de reticulation
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5545669A (en) 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
CN1211192A (zh) * 1995-09-18 1999-03-17 美国陆军医疗材料研究指挥部 生产非共价复合的多价蛋白体亚基疫苗的改进方法
US6821331B2 (en) * 2003-04-09 2004-11-23 Wisconsin Alumni Research Foundation Protein-polysaccharide hybrid hydrogels
EP1522585A1 (fr) * 2003-10-09 2005-04-13 Plant Research International B.V. Molécules porteuses chimères pour la production de vaccins absorbés au niveau des muqueuses
AU2007284878B2 (en) * 2006-08-07 2013-01-17 President And Fellows Of Harvard College Protein matrix vaccines and methods of making and administering such vaccines

Also Published As

Publication number Publication date
EP2056871A2 (fr) 2009-05-13
BRPI0715396B8 (pt) 2021-05-25
DK2056871T3 (en) 2018-02-26
US9216223B2 (en) 2015-12-22
US20080095803A1 (en) 2008-04-24
BRPI0715396B1 (pt) 2019-02-19
US20160136257A1 (en) 2016-05-19
KR20090066272A (ko) 2009-06-23
JP2014058530A (ja) 2014-04-03
ES2658851T3 (es) 2018-03-12
KR101446238B1 (ko) 2014-10-01
TWI565713B (zh) 2017-01-11
US8642042B2 (en) 2014-02-04
CA2660022A1 (fr) 2008-02-21
CA2660022C (fr) 2014-11-04
US9533032B2 (en) 2017-01-03
WO2008021076A3 (fr) 2008-12-04
EP2056871B1 (fr) 2017-11-15
EP2056871A4 (fr) 2010-04-14
AU2007284878A1 (en) 2008-02-21
EP3260134A1 (fr) 2017-12-27
BRPI0715396A2 (pt) 2013-11-26
WO2008021076A2 (fr) 2008-02-21
JP2010500354A (ja) 2010-01-07
AU2007284878B2 (en) 2013-01-17
JP5745221B2 (ja) 2015-07-08
TW200823230A (en) 2008-06-01
US20140186399A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
CY1123739T1 (el) Αντισωματα anti-cd38
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
WO2010037395A3 (fr) Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
MX363307B (es) Plataformas para suministro de antigenos.
WO2006126981A3 (fr) Compositions et methodes destinees a la vaccination par voie muqueuse
WO2005097211A3 (fr) Compositions adjuvantes ameliorant la reponse immunitaire a des vaccins et methodes d'utilisation
WO2008040362A3 (fr) Génération d'une réponse immune spécifique du cancer contre muc1 et anticorps dirigés contre muc1 spécifiques du cancer
PH12013502192A1 (en) Antibodies against human angiopoietin 2
TW200716646A (en) (S)-N-methylnaltrexone
MY169837A (en) Immunogenic compositions of staphylococcus aureus antigens
MY172421A (en) Immunostimulatory oligonucleotides
MX2011003842A (es) Direccion de celulas que presentan antigeno con inmunonanoterapeuticos.
EP1735010A4 (fr) Methodes, compositions et preparations pour administration de modificateurs de reponse immunitaire (irm)
EA201100268A1 (ru) Вакцина
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
WO2012027365A3 (fr) Formes pharmaceutiques multi-épitopes ciblées servant à l'induction d'une réponse immunitaire dirigée contre des antigènes
MA32819B1 (fr) Vaccin combine notamment contre la coqueluche acellulaire
MX354924B (es) Molecula portadora que comprende un antigeno spr0096 y un spr2021.
WO2009135199A3 (fr) Compositions vaccinales et procédés
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
WO2007078879A3 (fr) Compositions de lipopeptides et leurs procédés d'utilisation

Legal Events

Date Code Title Description
FG Grant or registration